3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
223
Carboplatin
218
Cisplatin
205
Paclitaxel
182
Gemcitabine
149
Docetaxel
127
Capecitabine
114
Dexamethasone
102
Pemetrexed
101
Cyclophosphamide
101
Specimen Handling
99
Magnetic Resonance Spectroscopy
97
Oxaliplatin
96
Radiotherapy
95
Doxorubicin
91
Fluorouracil
87
Bevacizumab
83
Nivolumab
74
Leucovorin
72
Rituximab
70
Vincristine
67
durvalumab
66
Lenalidomide
63
Etoposide
62
atezolizumab
61
Radiation
61
Irinotecan
60
130-nm albumin-bound paclitaxel
57
Prednisone
56
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
amino-acid, glucose, and electrolyte solution
×
1 year
×
Clear all
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled